Product Description
a novel _-melanocyte-stimulating hormone analog, for prevention of AKI in postoperative cardiac surgery patients. ABT-719 treatment did not lower AKI incidence using AKIN criteria, influence the elevations of novel biomarkers, or change 90-day outcomes in patients after cardiac surgery. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27543797/)
Mechanisms of Action: DNA Gyrase Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Kidney Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| M13-958 | P2 |
Terminated |
Acute Kidney Injury |
2014-05-01 |
2019-03-19 |
Treatments |
|
| 2012-005710-19 | P2 |
Terminated |
Acute Kidney Injury |
2014-04-08 |
2022-03-13 |
Treatments |
|
| 2012-003942-33 | P2 |
Completed |
Acute Kidney Injury |
2014-03-07 |
2022-03-13 |
Treatments |
|
| M13-796 | P2 |
Completed |
Acute Kidney Injury |
2014-03-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|